AUTOIMMUNE MEDIATED SUICIDAL BEHAVIOR



Cite item

Full Text

Abstract

Abstract

There is a known autoimmune disease, which is called «anti-NMDA receptor encephalitis», or «Dalmau encephalitis» (named after its discoverer). It is associated with the presence of high titers of antibodies to a certain epitope of the NR1 subunit of NMDA receptors in the blood and/or in the cerebrospinal fluid. This disease in its classic form is accompanied by severe mental (depression, delusions, hallucinations, anxiety, sleep disorders, cognitive impairment, catatonia, etc.) and neurological (convulsions, dyskinesias) symptoms, disturbances of consciousness and autonomic regulation (regulation of respiration, temperature, blood pressure, heart rhythm), as well as with suicidality, which seems to be disproportionate to the severity of mental disturbances. However, there are also «non-classical» forms of anti-NMDA receptor encephalitis. These can manifest with exclusively psychiatric symptoms (for example, depression, psychosis, suicidal behavior), without characteristic neurological symptoms and/or disorders of autonomic regulation. In some of these cases, the correct diagnosis of anti-NMDA receptor encephalitis was delayed by months, years or even decades. In addition, in recent decades, increasing evidence had accumulated that in some patients with so-called «classical» mental disorders, such as schizophrenia, bipolar affective disorder, depressive disorders — and especially in those who show resistance to traditional psychopharmacotherapy — elevated titers of anti-NMDA receptor antibodies can be detected in their blood and/or in their cerebrospinal fluid. It has also been shown that elevated blood titers of anti-NMDA receptor antibodies are often detected in post-mortem examinations of suicide victims. Anti-NMDA receptor antibody titers in psychiatric patients correlate well with a recent history of suicide attempts and/or with current active suicidal ideation. Some of these patients may benefit from aggressive immunosuppressive therapy that is similar to the regimens normally used to treat «classical» anti-NMDA receptor encephalitis with neurological and autonomic manifestations. This might stop their suicidal ideation and/or help in overcoming their resistance to psychopharmacotherapy. This article presents a description and analysis of three clinical cases of patients with various mental disorders, acute suicidality and elevated titers of anti-NMDA receptor antibodies, in whom such therapy has been effective.

About the authors

Yuri Vitalevich Bykov

Stavropol State Medical University Under the Supervision of Ministry of Health, Russian Federation

Email: yubykov@gmail.com
ORCID iD: 0000-0002-9376-7854
SPIN-code: 8201-6023
Scopus Author ID: 230866
ResearcherId: K-1888-2016
https://independent.academia.edu/YuriBykov

Candidate of Medical Sciences, Associate Professor at the Cathedra of Anaesthesiology and Reanimatology

Russian Federation, Russian Federation, Stavropol, str. Mira, 310

Anastasia Yurievna Bykova

Stavropol State Medical University Under Supervision of the Ministry of Health, Russian Federation

Email: iambykovanastasia@yandex.ru

Ordinator at Cathedra of Neurology, Neurosurgery and Medical Genetics

Russian Federation, Russian Federation, Stavropol, 355017, str. Mira, 310

Roman Alexandrovich Bekker

David Ben-Gurion University at Negev

Author for correspondence.
Email: romanbekker2022@gmail.com
ORCID iD: 0000-0002-0773-3405
SPIN-code: 9945-6754
Scopus Author ID: 854937
ResearcherId: J-7724-2016
https://bgu.academia.edu/RomanBekker

M. Sc. in Computer Sciences, Research Officer at Laboratory of Autonomous Robotics, Department of Electronic Engineering and Computer Sciences

Israel, Israel, Beer-Sheba, 84105, David Ben-Gurion Blvd., 1

References

  1. Cameron C.M., Nieto S., Bosler L., Wong M., Bishop I., Mooney L., Cahill C.M. Mechanisms Underlying the Anti-Suicidal Treatment Potential of Buprenorphine. Adv. Drug. Alcohol. Res., 2021, Vol. 1, p. 10009. doi: 10.3389/adar.2021.10009.
  2. Dalmau J., Tüzün E., Wu H., Masjuan J., Rossi J.E., Voloschin A., Baehring J.M., Shimazaki H., Koide R., King D., Mason W., Sansing L.H., Dichter M.A., Rosenfeld M.R., Lynch D.R. Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Ann. Neurol., 2007, Vol. 61, no. 1, pp. 25-36. doi: 10.1002/ana.21050.
  3. Dalmau J. Pregnancy, N-Methyl-D-Aspartate Receptor Antibodies, and Neuropsychiatric Diseases. Ann. Neurol., 2020, Vol. 87, no. 2, pp. 324-325. doi: 10.1002/ana.25654.
  4. Gulec B., Kurucu H., Bozbay S., Dikmen Y., Sayman H., Tuzun E., Tutuncu M., Uygunoglu U., Yalcinkaya C., Saip S., Siva A. Co-existence of multiple sclerosis and anti-NMDA receptor encephalitis: A case report and review of literature. Mult. Scler. Relat. Disord., 2020, Vol. 42, p. 102075. doi: 10.1016/j.msard.2020.102075.
  5. Hans D., Rengel A., Hans J., Bassett D., Hood S. N-Acetylcysteine as a novel rapidly acting anti-suicidal agent: A pilot naturalistic study in the emergency setting. PLoS One, 2022, Vol. 17, no. 1, p. e0263149. doi: 10.1371/journal.pone.0263149.
  6. Hansen N., Timäus C. Autoimmune encephalitis with psychiatric features in adults: historical evolution and prospective challenge. J. Neural Transm. (Vienna)., 2021, Vol. 128, no. 1, pp. 1-14. doi: 10.1007/s00702-020-02258-z.
  7. Ide T., Kawanami T., Tada Y., Eriguchi M. Overlapping rheumatoid meningitis with anti-N-methyl-D-aspartate receptor encephalitis: A case report. Clin. Case Rep., 2023, Vol. 11, no. 4, p. e7199. doi: 10.1002/ccr3.7199.
  8. Jaka S., Singh S., Vashist S., Pokhrel S., Saldana E., Sejdiu A., Taneja S., Arisoyin A., Mogallapu R., Gunturu S., Bachu A., Patel R.S. Pediatric anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis: Exploring psychosis, related risk factors, and hospital outcomes in a nationwide inpatient sample: A cross-sectional study. PLoS One, 2024, Vol. 19, no. 2, p. e0296870. doi: 10.1371/journal.pone.0296870.
  9. Kelleher E., McNamara P., Dunne J., Fitzmaurice B., Heron E.A., Whitty P., Walsh R., Mooney C., Hogan D., Conlon N., Gill M., Vincent A., Doherty C.P., Corvin A. Prevalence of N-Methyl-d-Aspartate Receptor antibody (NMDAR-Ab) encephalitis in patients with first episode psychosis and treatment resistant schizophrenia on clozapine, a population based study. Schizophr. Res., 2020, Vol. 222, pp. 455-461. doi: 10.1016/j.schres.2019.11.023.
  10. Kruse J.L., Lapid M.I., Lennon V.A., Klein C.J., Toole O.O., Pittock S.J., Strand E.A., Frye M.A., McKeon A. Psychiatric Autoimmunity: N-Methyl-D-Aspartate Receptor IgG and Beyond. Psychosomatics, 2015, Vol. 56, no. 3, pp. 227-241. doi: 10.1016/j.psym.2015.01.003.
  11. León-Caballero J., Pacchiarotti I., Murru A., Valentí M., Colom F., Benach B., Pérez V., Dalmau J., Vieta E. Bipolar disorder and antibodies against the N-methyl-d-aspartate receptor: A gate to the involvement of autoimmunity in the pathophysiology of bipolar illness. Neurosci. Biobehav. Rev., 2015, Vol. 55, pp. 403-412. doi: 10.1016/j.neubiorev.2015.05.012.
  12. Leypoldt F., Titulaer M.J., Aguilar E., Walther J., Bönstrup M., Havemeister S., Teegen B., Lütgehetmann M., Rosenkranz M., Magnus T., Dalmau J. Herpes simplex virus-1 encephalitis can trigger anti-NMDA receptor encephalitis: case report. Neurology, 2013, Vol. 81, no. 18, pp. 1637-1639. doi: 10.1212/WNL.0b013e3182a9f531.
  13. Magen E., Geishin A., Lauden A. Rapid Improvement of Treatment-Resistant Major Depression During the Administration of Low-Dose Oxycodone. J. Clin. Psychopharmacol., 2021, Vol. 41, no. 1, pp. 81-83. doi: 10.1097/JCP.0000000000001311.
  14. Rainey K., Gholkar B., Cheesman M. Anti-NMDA receptor encephalitis: an easily missed diagnosis in older patients. Age Ageing, 2014, Vol. 43, no. 5, pp. 725-726. doi: 10.1093/ageing/afu098.
  15. Reeves R.R., Cox S.K. Similar effects of tramadol and venlafaxine in major depressive disorder. South Med. J., 2008, Vol. 101, no. 2, pp. 193-195. doi: 10.1097/SMJ.0b013e3181616e66.
  16. Senda M., Bessho K., Oshima E., Sakamoto S., Tanaka K., Tsutsui K., Kanbayashi T., Takaki M., Yoshimura B. Anti-Inflammatory Therapy and Immunotherapy Were Partially Effective in a Patient With Anti-N-Methyl-D-Aspartate Receptor Antibodies and a Special Subgroup of Treatment-Resistant Schizophrenia. J. Clin. Psychopharmacol., 2016, Vol. 36, no. 1, pp. 92-93. doi: 10.1097/JCP.0000000000000439.
  17. Singh B., Voort J.V., Pazdernik V.K., Frye M.A., Kung S. Treatment-resistant depression patients with baseline suicidal ideation required more treatments to achieve therapeutic response with ketamine/esketamine. J. Affect. Disord., 2024, Vol. 351, pp. 534-540. doi: 10.1016/j.jad.2024.01.262.
  18. Tong J., Huang J., Luo X., Chen S., Cui Y., An H., Xiu M., Tan S., Wang Z., Yuan Y., Zhang J., Yang F., Li C.R., Hong L.E., Tan Y. Elevated serum anti-NMDA receptor antibody levels in first-episode patients with schizophrenia. Brain Behav. Immun., 2019, Vol. 81, pp. 213-219. doi: 10.1016/j.bbi.2019.06.017.
  19. Vitaliani R., Mason W., Ances B., Zwerdling T., Jiang Z., Dalmau J. Paraneoplastic encephalitis, psychiatric symptoms, and hypoventilation in ovarian teratoma. Ann. Neurol., 2005, Vol. 58, no. 4, pp. 594-604. doi: 10.1002/ana.20614.
  20. Wallengren S., Johansson B.A., Rask O. Acute manic state with psychotic features in a teenager with autoimmune encephalitis: a case report. J. Med. Case Rep., 2021, Vol. 15, no. 1, p. 295. doi: 10.1186/s13256-021-02879-2.
  21. Wang H. COVID-19, Anti-NMDA Receptor Encephalitis and MicroRNA. Front Immunol., 2022, Vol. 13, p. 825103. doi: 10.3389/fimmu.2022.825103.
  22. Wang P.R., Yavi M., Lee H., Kotb Y., Shora L., Park L.T., Zarate C.A. Jr. An Open-Label Study of Adjunctive Dextromethorphan/Quinidine in Treatment-Resistant Depression. J. Clin. Psychopharmacol., 2023, Vol. 43, no. 5, pp. 422-427. doi: 10.1097/JCP.0000000000001738.
  23. Wasserman D. Oxford textbook of suicidology and suicide prevention. – Oxford University Press, 2020.
  24. Yang P., Li L., Xia S., Zhou B., Zhu Y., Zhou G., Tu E., Huang T., Huang H., Li F. Effect of Clozapine on Anti-N-Methyl-D-Aspartate Receptor Encephalitis With Psychiatric Symptoms: A Series of Three Cases. Front Neurosci., 2019, Vol. 13, p. 315. doi: 10.3389/fnins.2019.00315.

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) Bykov Y., Bykova A.Y., Bekker R.A.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № 77 - 11525 от 04.01.2002.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies